In other studies it has been demonstrated that ePTFE treated grafts with TDMAC in Heparin also resulted in reduced thrombogenicity of the graft.
Other studies include the quantification of platelet emboli downstream from a vascular prosthesis, utilizing an isolated muscle technique which permits continuous monitoring of the microcirculation in the cremaster muscle. Current studies demonstrated that TDMAC Heparin on ePTFE microvascular prostheses not only improved graft patency rates but enhanced perfusion and reduced microemboli.
Ongoing investigations include the isolation and attachment of microvascular endothelial cells to ePTFE vascular graft material. Pretreatment of the graft material with denucleation and TDMAC with and without fibronectin demonstrated a highly significant retention of microvascular endothelial cells to the prosthesis. Current studies are underway to evaluate the degree to which these microvascular endothelial cells are metabolically active.
Current Appointments & Affiliations
Education, Training & Certifications
Duke University · 1964 M.D.